INTRODUCTION
Patients with cirrhosis are at risk for a variety of complications including ascites, hepatic encephalopathy, esophageal or gastric varices, and hepatocellular carcinoma (HCC). The development of ascites, encephalopathy, or bleeding varices defines the transition from compensated to decompensated cirrhosis, a change that is associated with a marked decrease in survival, from 12 years to approximately 2 years after initial diagnosis [1] . A pressing need exists to develop strategies to prevent or slow the transition to decompensated cirrhosis, improve management of complications including HCC, and ensure patients are referred for liver transplantation when appropriate.
Recently, the Practice Metrics Committee of the American Association for the Study of Liver Disease (AASLD) developed quality measures in the care of patients with cirrhosis, identifying process and outcome measures for the management of ascites, gastric and esophageal varices, hepatic encephalopathy, HCC screening, and evaluation for liver transplantation [2] . The final 46 metrics were intended to drive quality improvement and allow providers to deliver high-value care to patients with cirrhosis. Based on this assessment, there is considerable room for physicians to improve on the metrics laid out by the AASLD.
Prior studies have also supported the need for improvement. While several published cost-effectiveness models have reported that performing screening for HCC is cost effective, the screening rate for HCC in the United States is under 20%, and substantial disparities exist in screening for those followed by primary care physicians compared to hepatology/gastroenterology subspecialists (16.9% vs 51.7%) [3] [4] [5] . This screening rate is likely lower in developing regions of the world, where many countries do not have national screening programs for the early detection of HCC and cost effectiveness has not been evaluated in these populations [6] . Retrospective studies in Veterans Health Administration cohorts show that less than one third of patients receive all recommended care in the management of cirrhosis-related ascites and even fewer receive all recommended care related to the screening and management of varices [7, 8] . Readmission rates among patients with cirrhosis are approximately 30% at thirty days and 50% at ninety days from hospital discharge [9, 10] . There are many potential reasons for these shortcomings. The limited supply of hepatologists, particularly in rural and underserved locations in the United States and worldwide, can make it difficult for patients with cirrhosis to access specialized care. Patients with cirrhosis require multidisciplinary, coordinated care for titration of their medications, frequent laboratory monitoring and vaccinations, and scheduling screening endoscopies and imaging. Yet, the shortage of hepatologists and limited appointment availably of primary care providers and gastroenterologists leaves many patients and their families with much of the burden of managing their disease.
There are significant challenges to the implementation of successful and widereaching quality improvement initiatives for patients with cirrhosis. While much of the care of individuals with cirrhosis in the United States is done through the care of hepatologists at academic medical centers, there are fewer than 600 board certified hepatologists in the United States, roughly one for every 550000 persons [11] . Although certified hepatologists may be best suited to implement change, their scarcity means that the majority of the burden of medical care for patients without access to hepatologists likely falls on primary care providers and gastroenterologists. As noted above, outcomes may be improved for patients with cirrhosis who have access to care under the guidance of hepatologists or gastroenterologists. These challenges are similar in other countries with many more patients with liver disease than specialized physicians available to provide such care. Innovative health care solutions will be critical to improve the care of patients with cirrhosis. Specifically, telemedicine (a broad term for medicine practiced at a distance) and mobile health (mHealth, the use of interactive and mobile devices such as mobile phones and tablets to improve health) could play a key role in closing the quality gap in the care of patients with liver disease by expanding the ability of hepatologists to provide care.
TELEMEDICINE IN THE CARE OF CHRONIC DISEASES AND LIVER DISEASE
Telemedicine is defined by the World Health Organization as the delivery of health care services from a distance by the use of telecommunications and virtual technology to provide health care outside of traditional health-care facilities. Three promising types of telemedicine for patients with cirrhosis are teleconsultation, televisits and telemonitoring, each of which have been used in the care of patients with liver disease [12] . Teleconsultation, in which a practitioner in one location presents a case to an expert in another location, has been used in some settings with encouraging results. One of the most well-known telemedicine interventions is through the Veterans Health Administration (VA) system, which implemented the Specialty Access NetworkExtension for Community Healthcare Outcomes (SCAN-ECHO) model to provide specialty consultation to practitioners in underserved areas regarding new treatment options for hepatitis C in case-based formats [13] . Developed at the University of New Mexico, the ECHO model has been successfully implemented in other locations, including Argentina [14] . It has also been used in the VA system for managing patients with chronic liver disease, with promising results suggesting increased screening rates for liver cancer and varices and a lower mortality in those that received the intervention [15] . Teleconsultation has also proved useful in determining which patients may be candidates for liver transplantation and who should proceed to formal evaluation [16] . Televisits, in which the patient has direct contact with a provider in another location, have been shown to be a feasible model in the treatment of hepatitis C (Table  1) , although they have not been well described in caring for patients with liver disease in other settings. Face-to-face telemedicine encounters for the treatment of hepatitis C have been successfully implemented in rural populations in California and Canada, and for helping patients with opioid use disorder during their attendance at an opioid substitution program [17] [18] [19] . A hybrid between a teleconsultation and televisit model is that of a provider to provider consultation, with the patient physically present with the less specialized provider. The consultant can advise the general gastroenterologist or primary care provider to elicit a particular history, to perform certain physical exam maneuvers, or advise on a treatment plan. The physician physically present with the patient is responsible for the visit. While these hybrid consultations may be beneficial, this model has potential for difficulties with payment models and provider reimbursement.
Through telemonitoring, patients are monitored remotely for signs and symptoms of disease progression as well as objective data that may inform management. This approach has been described using smart tablets in patients in the perioperative period after liver transplantation and as a modality to monitor weight, vital signs, and laboratory values for pediatric liver transplant patients [20, 21] (Table 1) . A smartphonebased Stroop test has been validated for the diagnosis of covert hepatic encephalopathy [22] . Similarly, a "Patient Buddy App" that monitors symptoms such as weight gain along with medication adherence and daily sodium intake has shown potential to prevent hospital readmissions secondary to hepatic encephalopathy [23] . Additionally, an innovative program utilizing a telehealth platform with 4-G tablets, wireless blood pressure monitors, pulse oximeters and scales demonstrated efficacy in remotely monitoring patients for signs and symptoms of decompensation including hepatic encephalopathy, fluid overload, bleeding, and infections. Preventable readmissions were reduced from 33.8% in the standard of care arm to 0% at 30 and 90 days in the intervention arm. This intervention showed the ability for telemonitoring to reduce 30-d and 90-d readmissions while promoting patient-centered care [24] (Table  1) .
Studies performed in cirrhosis and liver transplant populations highlight the potentials of telemedicine and mHealth in liver disease, and yet, relative to other specialties and disease states, there is a paucity of literature implementing these innovative technologies with patients. Comparatively, the role of telemedicine in monitoring and facilitating treatment of patients with heart failure has been widely studied. Similar to patients with cirrhosis, patients with heart failure frequently require emergency hospitalizations and can have prolonged hospital admissions and frequent readmissions. Many of these hospitalizations could be avoided if patients received more education and had access to remote interactions with their medical teams, thereby empowering them to participate in the management of their own disease including modifications to their sodium intake or titration of medications. The heart failure literature is robust with randomized control trials, systematic reviews, and meta-analyses showing associations with reductions in mortality and hospitalizations for heart failure [25] . In addition, telemedicine in congestive heart failure can be economically beneficial; studies show savings that ranged from $5000 to over $50000 per year per patient [26] . Examples of innovative technologies that facilitate remote monitoring and treatment of patients with heart failure include telemonitoring devices that track hemodynamics, video-based nursing visits after hospital discharge, and a mobile application to set physical activity goals and provide feedback to individuals undergoing cardiac rehabilitation [27] [28] [29] . By contrast, the use of telemedicine in liver disease is limited to a handful of individual interventions and limited publications. Overall, the medical field has been slow in adapting telemedicine to interact with patients. According to data from the American Medical Association's 2016 Patient Practice Benchmark Survey, only 15.4% of physicians use telemedicine to interact with patients. Of all specialties, gastroenterologists were lowest-only 7.9% use telemedicine to interact with patients [30] .
THE POTENTIAL UNMET NEEDS
Effectively managing cirrhosis requires titrating medications, closely monitoring symptoms including changes in weight and cognitive abilities (as a surrogate for hepatic encephalopathy), and establishing regular reminders to schedule imaging, labs, and procedures. As such, cirrhosis is a medical condition ripe for telemedicine and mHealth interventions, with a myriad of potential targets for improvement.
IMPROVING SCREENING AND PREVENTATIVE CARE
Some of the most innovative uses of telemedicine and mHealth have been in dermatology and skin cancer screening, including use of smartphone applications for skin monitoring and melanoma detection [31] . Text message interventions have shown increases in screening rates for other cancers, including breast, cervical, and colorectal cancers [32] . Likewise, newly-developed smartphone applications aim to improve patient and provider education regarding screening for cancers, including colorectal and prostate cancer [33, 34] . For the care of patients with liver disease, the implementation of the SCAN-ECHO program for chronic liver disease by the Ann Arbor Veterans Affair Healthcare System found marked improvement in the frequency of HCC screening (42% vs 25%) and variceal surveillance (25% vs 15%) in patients whose providers consulted virtually with a liver specialist, compared to those who had no consultation at all [15] . Relatively simple, low cost interventions like text messaging, smartphone applications and teleconsultations could improve the rates of HCC screening and variceal screening-two interventions that have been shown to be costeffective in the care of patients with advanced liver disease-and ultimately improve outcomes for patients [4, 5, 35] .
IMPROVING ACCESS TO SPECIALTY CARE IN DISADVANTAGED POPULATIONS
Certain populations have difficulties engaging with specialized care for liver disease, including those who suffer from substance abuse and those living in rural locations.
In a retrospective cohort study of over 16000 persons with chronic liver disease, those who live more than 150 miles from a liver transplant center were shown to have a higher mortality and transplant-free mortality, highlighting significant geographic disparities that could be addressed by telemedicine [36] . Prior studies examining the use of teleconsultation in the treatment of hepatitis C and patients with opioid use disorder on methadone show the efficacy of these interventions in reaching groups that lack access or do not seek out medical care [19] . Strategies such as video conferencing with patients, primary care providers, and general gastroenterologists could play a significant role in increasing the reach of liver specialists to improve outcomes in patients with cirrhosis.
PROVIDING VALUE BASED HEALTHCARE
Approximately 30% of patients with cirrhosis are readmitted within 30 d of discharge, posing a significant cost burden to the United States healthcare system [9] . Given the promising cost-savings shown from using telemedicine among persons with heart failure, similar models should target patients with cirrhosis to reduce costs in the healthcare system, allow monitoring of patients in between visits, and facilitate communication for patients and providers between hospital discharge and clinic follow up. In one study in the care of patients after liver transplantation, general patient satisfaction of those who had telemedicine visits via video connection was similar to that of patients who had in-person visits. Moreover, telemedicine patients reported significantly less commute and waiting times compared to patients seen inperson [37] . Above all, the improved survival rates, as seen in the VA system with virtual consultations, indicate strong potential benefits to investing in telemedicine.
MONITORING INDIVIDUALS IN THEIR NATURAL ENVIRONMENTS
Patients suffering from chronic disease spend only a few hours with providers each year. This means that much of the burden of their disease management falls on the individual patients and their families during the remaining 5000 waking hours each year-including decisions on taking medications, following dietary restrictions, and making other choices that can significantly affect their health [38] . When patients with cirrhosis are seen in clinic, they often feel the need to hold their lactulose or diuretics to facilitate travel without frequent bathroom breaks. This disruption in medication dosing can lead to mild encephalopathy during their clinical assessment, and they may not be aware of everything conveyed to them during a visit. The use of televisits and telemonitoring strategies can give providers the opportunity to obtain assessments of patients in their home environment and gather more useful information than what they would otherwise obtain in a clinic visit.
BARRIERS TO OVERCOME
While telemedicine is a promising field, there are several barriers that will need to be overcome before its use can become widespread. Reimbursement remains an ongoing challenge, as payment varies for private payers and according to state laws, and Medicare currently reimburses for video consultation only for individuals in designated Health Professional Shortage Areas [12] . In addition, concerns regarding the quality of healthcare have been raised in telehealth, particularly with the limitations of the remote physical exam, the difficulty in establishing patient-physician trust remotely, and the fragmentation of care among multiple providers [39] . Consideration will also need to be given to ensuring adherence to state and national regulations and to establishing the appropriate infrastructure for patients with limited access or ability to use telecommunication technologies.
Additionally, the majority of interventions described to date are single arm interventions without control groups, making it difficult to estimate the true benefit of any intervention or to have a clear understanding of cost effectiveness. To understand downstream cost savings of such interventions, considerations will need to be given to defining clinical outcomes, clearly stating costs, and carefully defining control groups to better assess the potential benefits of an intervention.
CONCLUSION
The available literature suggests we are falling short of meeting a variety of quality metrics in the care of patients with cirrhosis-including preventative strategies such as cancer screening and treatment strategies such as the management of variceal bleeding and ascites. Interventions using telemedicine and mHealth provide logical solutions to improve screening rates, to reach disadvantaged rural populations, and to provide value-based care. Telemedicine may prove to be the guiding force in the coordination of care between episodes for patients with cirrhosis. There is a need for more resources to evaluate telemedicine interventions and to develop infrastructure to care for patients with cirrhosis. If executed effectively, telemedicine and mHealth technologies can provide cost savings and improve outcomes for patients with cirrhosis.
